Tag: Antibody

Categories
Health

Florida, Texas open Covid antibody remedy facilities as delta surge overwhelms hospitals

Florida, Texas open Covid antibody treatment centers as delta surge overwhelms hospitals

Florida Governor Ron DeSantis holds a press conference to announce the opening of a monoclonal antibody treatment center to help recover COVID-19 patients at Camping World Stadium in Orlando.

Paul Hennessy | LightRakete | Getty Images

Florida and Texas are opening free monoclonal antibody centers to treat a surge in Covid-19 patients in both states in the hopes that early intervention will help keep people out of hospitals and save more lives – even if they do The governors of both states are fighting local officials with mask and vaccination regulations.

Texas is building nine antibody infusion centers, Governor Greg Abbott announced on Friday, while Florida opened its fifth site on Wednesday. With the delta variant spike, coronavirus patients were occupied by more than 46% of Texas intensive care beds and more than half of Florida intensive care units as of Thursday, compared with 27% nationwide, according to the Department of Health and Social Affairs.

“What takes you to the hospital is the inflammation. People get inflammation in their lungs,” said Dr. Arturo Casadevall, Chair of Molecular Microbiology and Immunology at the Bloomberg School of Public Health at Johns Hopkins University, told CNBC in an interview. “So what these antibodies do is, if you give them to a patient early, they neutralize the virus.”

Abbott has firsthand experience of the treatment. His office announced Tuesday that he was receiving monoclonal antibody treatment from Regeneron after testing positive for Covid despite being fully vaccinated.

Although monoclonal antibodies like Regeneron and GlaxoSmithKline treatments are one of the few proven ways to fight the virus and reduce hospital stays, they were rarely used during the pandemic because they are awkward to administer. Monoclonal antibody treatments must be injected directly into the vein via an IV infusion, which requires time and dedicated medical staff, often using the same equipment reserved for chemotherapy patients.

The Food and Drug Administration issued emergency clearances to Regeneron’s treatment in November, saying it reduced hospital admissions for Covid “in patients at high risk for disease progression within 28 days of treatment.” GlaxoSmithKline just received emergency approval for its treatment with Vir Biotechnology in May and said it has reduced hospital stays and deaths in high-risk patients by about 85%.

The FDA approved both companies’ treatments for use in patients 12 years of age and older.

“Many patients who are examined by their doctors and referred for a monoclonal antibody infusion are less likely to be hospitalized,” said Teresa Farfan, spokeswoman for the Texas Division of Emergency Management, in an email to CNBC . “This will help ensure that resources are available in the hospitals to treat those with the most severe cases of the virus.”

Treatment centers couldn’t get there early enough as the Delta variant is driving cases to record highs in Florida. The state, which publishes its cases once a week on Fridays, last reported a record seven-day average of nearly 21,700 new infections, 12.6% more than a week ago, according to a CNBC analysis of data compiled by Hopkins.

Texas has been moving closer and closer to its record highs of more than 23,000 average cases per day in January in recent weeks, reporting a seven-day average of just over 15,400 new infections on Thursday, up from a seven-day average of around 3,000 a last month.

“Let me be very clear on this – both monoclonal and vaccines save lives,” said Christina Pushaw, spokeswoman for Florida Governor Ron DeSantis, in an email to CNBC. “They certainly aren’t mutually exclusive.”

More than 34% of the 50,706 registered inpatients in Florida have the coronavirus, as does over a quarter of the 51,337 registered inpatients in Texas, as measured Thursday. Abbott called 2,500 medical workers from across the country last week to help fight the virus and urged hospitals to build capacity by postponing election procedures.

A box and vial of the Regeneron monoclonal antibody can be seen at a new COVID-19 treatment site opened by Florida Governor Ron DeSantis at Camping World Stadium in Orlando following a press conference.

Paul Hennessy | LightRakete | Getty Images

While both Abbott and DeSantis have urged residents to get vaccinated, they still strictly oppose mask or vaccination regulations, saying it violates personal freedoms. Republican governors have banned local governments and school districts from requiring face-covering. Abbott has threatened $ 1,000 fines for those who fail to comply, and DeSantis said it will withhold pay from educators who prescribe masks.

With many children returning to classrooms this fall, local officials are pushing back. Several school districts in both states have defied their governors’ orders and restored their mask mandates, with appeals courts in Dallas and San Antonio issuing injunctions last week to circumvent the ban.

The Texas Supreme Court on Sunday blocked the injunctions, sided with Abbott and prevented school districts from issuing their own guidelines. Local officials say they plan to continue fighting Abbott in court, and President Joe Biden on Wednesday directed the education secretary to intervene “to protect our children.”

“This includes using all of its regulators and, if necessary, taking legal action against governors who try to block and intimidate local school officials and educators,” said Biden.

Dr. Bruce Farber, chief of infectious diseases at Northwell Health in New York, said states that don’t allow schools to prescribe masks are at great risk this fall.

“These states are gambling as I see it,” he said in an interview. “By not allowing masking and preventing masking and leaving it to the parents, (they) are really playing with fire.”

Categories
Health

As Virus Circumstances Surge, Biden Administration Encourages Extra Use of Antibody Remedies

As Virus Cases Surge, Biden Administration Encourages More Use of Antibody Treatments

WASHINGTON – Amid crowded hospitals and a relentless increase in Delta variant cases across the country, the Biden government on Thursday renewed its call on health care providers to use monoclonal antibody treatments that can help Covid-19 patients at risk of becoming very sick become.

Dr. Marcella Nunez-Smith, a White House Racial Health Advisor, said at a press conference that federal surge teams deployed to severely affected states were working to increase acceptance and confidence in the antibody drugs. They have already been given to more than 600,000 people in the United States during the pandemic, she said to prevent hospitalizations and save lives. President Donald J. Trump received such treatment when he was diagnosed with Covid-19 last year before being approved for emergency use.

In states where vaccination has stalled and cases have soared, treatments have become an important part of the federal strategy to reduce the number of the worst outbreaks, underscoring how many Americans remain at risk.

The distribution of doses ordered from medical providers increased fivefold from June to July. According to the Ministry of Health, around 75 percent of the orders come from regions of the country with low vaccination rates.

The government “remains ready to support states and territories and jurisdictions across the country to bring more people into contact with the treatments,” said Dr. Nunez-Smith on Thursday, despite stressing that vaccinations are still the best option for preventing Covid-19.

Jeffrey D. Zients, the White House’s Covid-19 response coordinator, said the Biden government has dispatched more than 500 federal workers to assist state health officials and hospitals in fighting the Delta variant, including rescue workers in Louisiana and Mississippi and Centers for Disease Control and prevention teams in Tennessee, Illinois and Missouri.

Dr. Nunez-Smith said the government was providing virtual drug delivery training to doctors and health care officials in Arizona, Nevada, Utah and Wyoming. In Arizona, federal teams are offering the treatments at two locations, where none of the Covid-19 patients who received them were subsequently hospitalized.

The treatments, which the federal government pays for and makes available to patients free of charge, mimic antibodies that the immune system naturally produces to fight the coronavirus. When given to patients soon after symptoms appear, typically by intravenous infusion, they have been shown to greatly reduce hospital stays and deaths. There is also evidence that it may have the potential to completely prevent the disease in certain people exposed to the virus. Unlike coronavirus vaccines, which take up to six weeks to provide full protection, the antibody treatments can be given to patients who are already ill with immediate effect.

The latest data from the Ministry of Health shows that almost half of the distributed range of treatments had been used by more than 6,000 hospitals and other provider locations by the end of last year. The federal government relies on providers and state health authorities to report their usage numbers and does not track the demographics of the patients receiving the medication.

Dr. Nunez-Smith said shipments to Florida, which is experiencing a devastating surge in virus cases, increased eight-fold in the last month, and more than 108,000 treatment courses were shipped across the country in July.

Updated

Aug. 12, 2021, 5:51 p.m. ET

Florida Governor Ron DeSantis on Thursday unveiled a “rapid response unit” for conducting Regeneron treatment in Jacksonville and said the state would establish similar locations in other cities.

Interest in the monoclonal antibodies was low throughout the pandemic. When they were approved last year, Regeneron and Eli Lilly’s treatments were expected to be in high demand and act as a bridge in fighting the pandemic before the vaccinations ramp up. They were tirelessly promoted by Mr. Trump, who called Regeneron treatment a “cure,” and by senior health officials in his administration.

Even so, they ended up on refrigerator shelves in many places, even during the recent power surges. Many hospitals and clinics did not prioritize treatments because they were time consuming and difficult to administer when they needed to be administered via an intravenous infusion. Doctors can now give the most commonly used Regeneron treatment, subcutaneously or by injection.

Understand the state of vaccination and masking requirements in the United States

    • Mask rules. The Centers for Disease Control and Prevention in July recommended that all Americans, regardless of vaccination status, wear masks in public places indoors in areas with outbreaks, a reversal of the guidelines offered in May. See where the CDC guidelines would apply and where states have implemented their own mask guidelines. The battle over masks is controversial in some states, with some local leaders defying state bans.
    • Vaccination regulations. . . and B.Factories. Private companies are increasingly demanding coronavirus vaccines for employees with different approaches. Such mandates are legally permissible and have been confirmed in legal challenges.
    • College and Universities. More than 400 colleges and universities require a vaccination against Covid-19. Almost all of them are in states that voted for President Biden.
    • schools. On August 11, California announced that teachers and staff at both public and private schools would have to get vaccinated or have regular tests, the first state in the nation to do so. A survey published in August found that many American parents of school-age children are opposed to mandatory vaccines for students but are more supportive of masking requirements for students, teachers, and staff who do not have a vaccination.
    • Hospitals and medical centers. Many hospitals and large health systems require their employees to receive a Covid-19 vaccine, due to rising case numbers due to the Delta variant and persistently low vaccination rates in their communities, even within their workforce.
    • new York. On August 3, New York City Mayor Bill de Blasio announced that workers and customers would be required to provide proof of vaccination when dining indoors, gyms, performances, and other indoor situations. City hospital staff must also be vaccinated or have weekly tests. Similar rules apply to employees in New York State.
    • At the federal level. The Pentagon announced that it would make coronavirus vaccinations compulsory for the country’s 1.3 million active soldiers “by mid-September at the latest. President Biden announced that all civil federal employees would need to be vaccinated against the coronavirus or undergo regular tests, social distancing, mask requirements and travel restrictions.

“These are important tools,” said Dr. Dan Barouch, a virologist at Beth Israel Deaconess Medical Center in Boston, who worked with Regeneron on a study that showed that the company’s antibody treatment could potentially prevent Covid-19 if given to people living with someone infected with the coronavirus . “They have shown significant therapeutic effects.”

Dr. Rajesh Gandhi, an infectious disease doctor at Massachusetts General Hospital who reviewed the study, said the evidence of the benefits of antibody treatments has only grown stronger in recent months. He said more needs to be done to educate doctors and patients about how effective they can be.

“Patients need to know that they have to call their doctors and ask about treatments,” he said. “In 2020, people with mild covid were told to stay home. That message needs to become a more proactive one. “

Regeneron has aired a number of television commercials for his treatment this year.

Virtually all Covid-19 patients who receive monoclonal antibodies during the delta surge will receive the type made by Regeneron, one of three approved by the Food and Drug Administration during the pandemic. The company estimated last week that its treatment is now reaching more than a quarter of eligible patients, up from less than 5 percent at the start of the pandemic.

The FDA last month expanded its emergency approval for Regeneron treatment so that it can be used to attempt to prevent Covid-19 in a small number of high-risk patients. This includes people with certain health conditions who are not vaccinated or who may not develop an adequate immune response, who have been exposed to the virus, or who live in nursing homes or prisons. It, like the other monoclonal antibody treatments, had previously only been available to high-risk patients who had already tested positive for the virus.

The federal government indefinitely suspended delivery of Eli Lilly’s first approved monoclonal antibody treatment in June, as new laboratory data suggested it wouldn’t work well in cases caused by the beta and gamma variants.

The government has not ordered any doses of a third treatment of GlaxoSmithKline and Vir that has been minimally used to date. Kathleen Quinn, a spokeswoman for GlaxoSmithKline, said the treatment is available at health facilities in 26 states and US territories.

Categories
Health

Regeneron to request FDA clearance for antibody drug as preventative remedy

Regeneron to request FDA clearance for antibody drug as preventative treatment

View of Regeneron Pharmaceuticals corporate, research and development headquarters on Old Saw Mill River Road in Tarrytown, New York.

Lev Radin | LightRocket | Getty Images

Regeneron Pharmaceuticals announced Monday that it would ask the Food and Drug Administration to approve the use of its Covid-19 antibody therapy as a preventative treatment.

The therapy, given to former President Donald Trump shortly after he was diagnosed with Covid-19 last year, has already been approved by the FDA to treat adults with mild to moderate Covid-19 and pediatric patients aged 12 and over approved age who tested positive for the virus and is at high risk of serious illness.

Regeneron said it plans to expand the use of its treatment in the United States after a Phase 3 clinical study jointly conducted by the National Institutes of Health found the drug reduced the risk of symptomatic infections in individuals by 81%.

The company also said that people who were symptomatic and treated with the drug resolved their symptoms an average of two weeks faster than those who received a placebo.

“As more than 60,000 Americans continue to be diagnosed with COVID-19 every day, the REGEN-COV antibody cocktail can help provide immediate protection to unvaccinated people exposed to the virus,” said Dr. George Yancopoulos, President and Chief Scientific Officer of Regeneron, said in a press release.

The study included 1,505 people who were not infected with the virus but lived in the same household as someone who recently tested positive. Participants received either a dose of Regeneron therapy or a placebo.

The company said 41% of the people in the study were Hispanic and 9% were Black. Additionally, 33% of the participants were obese and 38% were 50 years and older, according to the company.

Regeneron therapy belongs to a class of treatments known as monoclonal antibodies, which act as immune cells to fight infections. Monoclonal antibody treatments attracted widespread attention after it was revealed that Trump had received Regeneron’s drug in October.

In recent months, public health officials have raised concerns that emerging, highly contagious variants of coronavirus could threaten monoclonal antibodies on the market. Dr. However, Myron Cohen, who leads monoclonal antibody efforts for the NIH-sponsored COVID Prevention Network, said the drug has shown that it will retain its effectiveness against new strains.

As the world’s attention has shifted to giving Covid-19 vaccines, health experts say treatments are also crucial to ending the pandemic, which, according to compiled data, has topped 31.1 million in just over a year Infected Americans and killed at least 561,800 people from Johns Hopkins University.

Categories
Health

Blood Clots Linked to AZ Vaccine Stem From Uncommon Antibody Response

Blood Clots Linked to AZ Vaccine Stem From Rare Antibody Reaction

The antibodies resulted in a condition called thrombotic thrombocytopenia, which caused both clotting and abnormal bleeding. The researchers suggested calling the newly identified version in these patients “vaccine-induced immunothrombotic thrombocytopenia” or VITT.

Scientists have put forward various theories of what triggers the immune response. The AstraZeneca vaccine uses a chimpanzee adenovirus to transport DNA into recipients and trigger an immune response against the coronavirus. Laboratory research has shown that the chimpanzee virus or DNA could be causing the problem. Some researchers have suggested that bleeding from the injection mixed with the vaccine could bring platelets into the crosshairs of the immune system.

Dr. Greinacher called the theories plausible but unproven.

The article described special blood tests that could help diagnose the disorder and differentiate it from other, more common, clotting problems unrelated to the vaccine. The research team suggested treatment with a blood product called intravenous immunoglobulin, which is used to treat various immune disorders. Dr. Greinacher compared the treatment to putting out a fire.

Medicines called anticoagulants or blood thinners can also be given. However, the researchers advised against prescribing a commonly used heparin because the vaccine-induced condition is very similar to a severe reaction that is rarely seen in people given heparin.

The second report from Norway described five patients, one male and four female health workers aged 32 to 54, who had blood clots and bleeding seven to ten days after receiving the AstraZeneca vaccine. Four had severe blood clots in the brain and three died. Severe headache was one of her early symptoms. Like the German patients, they all had high levels of antibodies that could activate blood platelets.

The team from Norway also recommended intravenous immunoglobulin treatment. The researchers said the disorder is rare but “a new phenomenon with devastating effects on otherwise healthy young adults,” and they suggested it might be more common than previous studies with the AstraZeneca vaccine had shown.

On Friday, European regulators also said they were reviewing reports of some blood clot cases that have occurred in people who had received the Johnson and Johnson vaccine. In the United States, federal agencies are investigating reports of another type of unusual blood disorder in which a few dozen people who received either the Pfizer-BioNTech or Moderna vaccines experienced steep decreases in platelet counts.

Benjamin Mueller and Melissa Eddy contributed to this.

Categories
Health

GlaxoSmithKline asks FDA for emergency authorization for antibody drug

GlaxoSmithKline asks FDA for emergency authorization for antibody drug

In this photo illustration, the UK multinational pharmaceutical company GlaxoSmithKline (GSK) logo is displayed on a smartphone with a computer model of the COVID-19 coronavirus in the background.

Budrul Chukrut | SOPA pictures | Getty Images

GlaxoSmithKline and Vir Biotechnology filed Friday with the Food and Drug Administration for emergency approval for their monoclonal antibody drug.

The companies apply for the permit for high risk individuals aged 12 and over.

The FDA filing is based on an interim analysis of a Phase 3 study evaluating the drug for the early treatment of Covid-19 in adults at high hospital risk. The drug reduced hospital admissions or death from Covid by 85% compared to a placebo. The test results were based on 583 patients.

“As a result, the Independent Data Monitoring Committee recommended that the study be discontinued because of the evidence of profound effectiveness for the registration,” the company said in a statement.

Companies began testing the antibody on early-stage Covid patients in August in hopes of preventing symptoms from getting worse. Antibody drugs gained attention after they were used to treat former President Donald Trump last year.

U.S. health officials say antibody drugs already approved for use – by Regeneron and Eli Lilly – are not being used adequately.

GSK said the companies would also continue talks with the European Medicines Agency and other global regulators to make the drug available to Covid patients as soon as possible.

-Reuter contributed to this report.

Categories
Business

Vaxart shares plunge on weak antibody response to oral vaccine

Vaxart shares plunge on weak antibody response to oral vaccine

An experimental coronavirus oral vaccine showed promising results in an early clinical trial of 35 healthy adults, Vaxart of South San Francisco said on Wednesday. Despite the results, Vaxart’s stock fell about 57%.

Vaxart scientists divided volunteers between the ages of 18 and 54 into three groups. The first group received two low doses of the vaccine – called VXA-CoV2-1 – 29 days apart, while the remaining groups received a single low or high dose.

The vaccine, contained in a small tablet, produced a type of T cell responsible for killing virus-infected cells in about 75% of the volunteers who received a single low or high dose. The reported reactions are higher than with the vaccines from Moderna and Pfizer.

However, neutralizing antibodies were not detected in volunteers after a single dose, Vaxart said. Researchers believe that the antibodies play an important role in the defense of cells against the virus. The company said it is currently testing second-dose antibody responses after antibodies were detected in two-dose volunteers’ nasal swab samples.

Isaac Bogoch, an infectious disease specialist and professor at the University of Toronto, said the company’s shares could fall after the first dose due to the lack of neutralizing antibodies.

“The immune response is diverse,” he said, adding that one aspect of the immune response is to make antibodies, especially neutralizing antibodies. “While it is great to see that there seems to be a decent T-cell response, the lack of antibodies detected is problematic and can reduce the effectiveness of this vaccine.”

The company said no serious adverse events were reported in the Phase 1 study, with side effects generally being mild. Volunteers reported common side effects such as headache and fatigue, and there was a “slight increase” in the high-dose group of loose stool cases, the company said.

The data will be presented on Wednesday afternoon at the New York Academy of Sciences symposium.

“The most exciting thing about the [phase one data] is that we can get a very, very strong T-cell response even after one dose, “Sean Tucker, Vaxart’s chief scientific officer, told CNBC in a telephone interview, adding that T-cells do compared to antibodies fighting the virus is likely to be “underestimated”.

The biotech company said the vaccine has the potential to provide better protection against current and emerging strains of the virus than existing vaccines. Moderna, Johnson & Johnson and Novavax have announced in the past few days that their vaccines may be less effective against B.1.351, a highly contagious strain found in South Africa. US officials have raised concerns that Covid may continue to mutate and defy the protection of existing vaccines.

Vaxart’s vaccine contains DNA instructions for making the spike protein that allows the virus to enter human cells, as well as instructions for making the N protein, which is involved in other processes. Tucker said the inclusion of the N protein could cause the vaccine to retain its ability to work against emergent strains.

Many other vaccines under development chose spike protein as a “primary target,” he said. “But the problem with that [spike] Protein it definitely mutates more over time. We also added the N protein, which is highly conserved in the virus. “

According to Vaxart, the vaccine is the only oral tablet in the US that has been tested in humans. Similar technology is being used to develop vaccines against influenza and norovirus.

The company was investigated and investigated by the federal government late last year for allegedly exaggerating its involvement in Operation Warp Speed, former President Donald Trump’s vaccines and treatments program. A June press release said that “Vaxart’s Covid-19 vaccine has been selected for US government Operation Warp Speed,” which rocketed its stocks.

However, it found the company had received no federal government funding for vaccine doses and was only participating in preliminary U.S. studies to identify potential areas for possible Warp Speed ​​partnership and support, according to the New York Times.

Tucker told CNBC the company is in talks with the US and other governments to find possible ways to collaborate on its vaccine.

If Vaxart’s vaccine goes through other clinical trials and US approval, it could offer advantages over needle-based vaccines.

Dr. Paul Offit, a member of the FDA’s Advisory Committee on Vaccines and Allied Biological Products, said that an orally taken vaccine may be better accepted by the public who may be afraid of needles. Two US-approved Covid-19 vaccines – from Pfizer and Moderna – are injected into the arm and require two injections three to four weeks apart.

Vaxart said his vaccine is stable even at room temperature and does not require a freezer, which means it “can be stored and delivered to mass populations around the world”. In comparison, Pfizer’s vaccine must be stored in ultra-cold freezers that keep it between minus 112 and minus 76 degrees Fahrenheit. Moderna vaccine must be delivered between 13 and 5 degrees Fahrenheit.

Vaxart said the vaccine also doesn’t require any special medical training and can be taken at home. This will help comply with social distancing guidelines while relieving the burden on the health system.

The company said it was still critical whether it was single- or two-dose therapy.

A phase 2 study is expected “in the next few months,” Tucker said. In its “Fastest Accelerated Timeline,” the company expects Phase two and three studies to be completed by early 2022.

–CNBC’s Hugh Son contributed to this report.

Categories
Health

LabCorp CEO says recipients don’t want antibody check afterward

West Virginia Gov. Jim Justice on nursing home rollout

Adam Schechter, CEO of LabCorp, on Tuesday urged Americans to get vaccinated against Covid-19 and told CNBC that recipients would not be advised to be tested for Covid antibodies afterwards.

“At the moment there is no recommendation for it. We still have to understand a lot more about the vaccines, know what is to be measured, how is to be measured,” Schechter told the Closing Bell.

The body’s immune system produces antibodies in response to a foreign pathogen and helps fight an infection. During the pandemic, antibody tests were used to determine if someone had previously been infected with the coronavirus.

Now that Covid vaccines are being given to millions of people, questions have been raised about what role antibody tests might play in determining whether a vaccine recipient is developing an immune response. In clinical studies, Moderna and Pfizer-BioNTech’s vaccines have been shown to be more than 94% effective in preventing symptomatic Covid-19.

In December, for example, Roche received emergency use approval from the U.S. Food and Drug Administration for a test to detect antibodies to the coronavirus spike protein. In a press release at the time, the Swiss diagnostics and pharmaceutical company claimed that the test could be valuable after someone had been vaccinated against Covid.

“Many current vaccine candidates aim to induce an antibody response against the SARS-CoV-2 spike protein,” the company said. “Tests that quantify antibodies to the spike protein could be used to measure the extent of this response and track that measurement over time.”

Schechter acknowledged that there might be a role for post-vaccination antibody testing but said, “We have a lot more to learn.”

“In the future, it might make sense to look at antibodies. It might make sense to look at T cells,” which are another element of the body’s immune response, he said. “Right now, as many people should be vaccinated as soon as possible, and there is no recommendation to have an additional blood test afterwards,” he added.

LabCorp’s shares closed the trading session Tuesday at around $ 220 apiece. The stock has soared more than 120% to $ 98 since its pandemic low on March 19.

Categories
Business

Covid variant present in South Africa ‘might evade’ Eli Lilly’s antibody drug: CEO

Covid variant found in South Africa ‘could evade’ Eli Lilly's antibody drug: CEO

Dave Ricks, chairman and CEO of Eli Lilly, told CNBC on Tuesday that he expected the company’s Covid-19 antibody drug to be effective against the variant of coronavirus found in the UK

However, he said the exposure observed in South Africa is likely to be more of a challenge.

“The South African variant … is cause for concern. It has more dramatic mutations to the spike protein that these antibody drugs target,” Ricks told Squawk Box. “In theory, it could evade our drugs.”

Eli Lilly’s antibody drug was approved for emergency use by the US Food and Drug Administration in November. The drug is aimed at people recently diagnosed with Covid-19 in hopes of preventing the need for hospitalization. Regeneron’s Covid-19 antibody treatment, which President Donald Trump received after contracting the disease, has also received limited approval from the FDA.

According to Ricks, Eli Lilly wants to work with the FDA to quickly test different versions of antibodies to see if they are against virus variants like the one in South Africa.

“We actually have a large library of these antibodies now that are pre-clinical,” said Ricks. “We could think of a very expedited way to study them in a month or two and then approve their use. That seems like a smart thing because this virus is mutating.”

Discovery of variants

Coronavirus variants originally found in the UK and South Africa have received significant attention in recent weeks. They are believed to be more transmissible – but not more deadly – than previous tribes. Even so, a more contagious virus that leads to more infections could continue to weigh on healthcare systems and lead to more deaths.

The discovery of these mutations also coincides with the introduction of Covid-19 vaccines from drug companies such as Pfizer and BioNTech, as well as Moderna. It has led to some questions about whether the vaccines – along with treatments for the disease – would keep their effectiveness.

In a CNBC interview on Monday, Dr. Ugur Sahin, CEO of BioNTech, confident that his vaccine, manufactured in partnership with Pfizer, will work against the strains of the virus found in the UK and South Africa.

Daniel O’Day, CEO of Gilead Sciences, told CNBC it was testing its remdesivir treatment against these new strains, but said Monday the antiviral drug would likely be effective. Antiviral drugs like remdesivir try to prevent the virus from replicating. In contrast, antibodies like Eli Lillys bind to the virus present in the body and try to neutralize it.

There have been no confirmed cases of the variant, which was first discovered in South Africa in America, but according to the Wall Street Journal, it was discovered in countries like Japan, South Korea, and Switzerland. According to the Centers for Disease Control and Prevention, there have been around 70 confirmed cases of the coronavirus variant in the US that were originally found in the UK.

“It seems clear that Lilly’s single antibody, and likely Regeneron’s cocktail, will stop this as well as the normal variant,” said Ricks of the UK-affiliated tribe. “We haven’t done a clinical study of this effect, but we do have pre-clinical data that strongly suggests that it won’t be a problem.”

Use of antibody therapies

After the FDA approved emergency use for their antibody therapies to Eli Lilly and later Regeneron, problems arose with actually delivering the drug, which requires an intravenous infusion, to Covid patients. In mid-December, CNBC reported that between 5% and 20% of the doses delivered had been administered.

That number is “climbing” now, Ricks said on Monday. He pointed to Alabama as a state where the antibodies are widespread. Alabama “basically runs out and refills every week,” he said.

“There are quite a few” from state to state, Ricks admitted. “We want all states to learn from these practices and really be able to use this medicine, as the benefit is that patients, especially seniors, are kept out of the hospital. We know if you are a senior and have Covid-19 and end up in a hospital hospital bed, the prospects are not good. “

Categories
Health

What to Know of Covid-19 Antibody Medication: Price, Availability and Extra

What to Know of Covid-19 Antibody Drugs: Cost, Availability and More

Two new antibody treatments have shown promise in keeping high-risk Covid-19 patients out of the hospital.

Although President Trump, who received Regeneron treatment in October and lauded it as a “cure,” received a boost in advertising, the drugs have not been widely distributed since they were approved for emergency use by the Food and Drug Administration last month.

Now federal and state health authorities are calling on patients and doctors to seek treatments.

Here’s what you need to know.

The two treatments by Eli Lilly and Regeneron are the first drugs specifically designed for Covid-19 and approved by the FDA. They are made from artificially synthesized copies of the antibodies that humans naturally produce when their immune systems fight off an infection. Eli Lilly’s drug consists of an antibody. Regeneron’s is a cocktail of two.

Early data showed that it can prevent hospitalization in people at high risk of serious complications from the disease. Clinical studies continue. The treatments are believed to help turn the virus off shortly after infection.

Treatments can be given to anyone who tests positive for the coronavirus, is at high risk of developing a severe form of the disease, and occurs within 10 days of symptoms first appearing.

This includes people who are at least 65 years old and those who are obese or have diseases such as diabetes.

The treatments are not approved for people who have already been hospitalized or need oxygen, as studies in these groups have not shown the drugs to work well.

Under agreements each company has made with the federal government, the doses are free, although some patients may have to pay for the administration of the drug, which must be infused by a healthcare provider, depending on insurance coverage.

Monoclonal antibody treatments are difficult and time consuming to manufacture, which has limited the number of doses made by drug manufacturers.

The federal government has bought 950,000 cans from Eli Lilly and 300,000 cans from Regeneron. Pharmaceutical companies have already dispensed hundreds of thousands of these doses, with the rest expected in late January.

Nobody knows, but many of the cans that have been distributed so far have remained unused and are sitting in hospital refrigerators.

While the federal government has nearly 532,000 doses of the two drugs available and nearly 291,000 doses have been shipped, neither the government nor the drug companies have complete data on how many of these doses have been given to patients.

The subset of hospitals that report data to the government on the number of doses administered has, on average, used only 20 percent of their supply, according to the Department of Health and Human Services.

The drugs are used unevenly across the country. Some hospitals cannot get enough doses. Others haven’t even used much of what they got so far.

Several factors have contributed to the underutilization: Hospitals are overwhelmed by the virus flood and are focusing on the first vaccines. And they need to be housed in their crowded facilities where the treatments can be infused over a period of hours without spreading the virus to others.

Some patients have been reluctant to engage in treatments, be it because they are unwilling to go to a clinic while feeling sick, lack of transportation, or because they perceive the drugs as connected people only for patients who are felt to be good. And the scarcity of treatments adds to their underuse as some hospitals withhold supplies for fear of leakage.

There is no single hotline or website that patients can use to find a provider who offers the treatments.

Many health systems have put in place ways to identify and contact eligible patients who have tested positive for the coronavirus at test sites or in doctor’s offices. However, these referral systems vary from municipality to municipality.

Eli Lilly’s support line for treatment is 1-855-545-5921. A Regeneron spokeswoman recommended that patients or doctors contact the state health department.

Dr. Daniel Skovronsky, Eli Lilly’s chief scientist, said he advises friends and family members to call the company’s hotline. “If you are persistent and you qualify, you will get it,” he said.